Posted by Michael Wonder on 26 Jul 2017
Health Canada approves Adcetris (brentuximab vedotin) for the post-ASCT consolidation treatment of patients with Hodgkin lymphoma at increased risk of relapse or progression
25 July 2017 - Approval based on positive phase 3 AETHERA clinical trial results. ...
Read more →